Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

13,481 total articles

Concorde International Group Secures Multi-Year Contracts Worth Over US$10 Million for Integrated Security Solutions in Singapore

Concorde International Group Secures Multi-Year Contracts Worth Over US$10 Million for Integrated Security Solutions in Singapore

Concorde International Group Ltd., a technology-enabled security solutions provider, announced it has secured multi-year contracts worth over US$10 million to deliver integrated security solutions across industrial zones, business districts, and community precincts in Singapore. The contracts involve deployment of the company's proprietary i-Guardi…

Barrick Announces Election of Directors

Barrick Announces Election of Directors

Barrick Mining Corporation announced the election of its board of directors, appointment of auditors, and approval of executive compensation at its 2026 Annual Meeting. The company confirmed strong shareholder support for its governance proposals, reinforcing stable management and oversight as it continues operations across 17 countries.

Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab

Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab

Tiziana Life Sciences announced initial Phase 2 clinical trial results revealing that intranasal foralumab significantly reduces brain inflammation in patients with Multiple System Atrophy (MSA), as measured by PET imaging. This represents the third neurological condition showing marked inflammation reduction with the therapy, which previously show…

Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress

Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress

Climb Bio, Inc., a clinical-stage biotech company, announced it will present new clinical data for its investigational drug budoprutug at the European Hematology Association 2026 Congress. The data includes safety and efficacy results from a Phase 1b/2a trial in patients with primary immune thrombocytopenia, highlighting budoprutug’s potential as a…

Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting

Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting

Cabaletta Bio presented encouraging clinical and translational data for its autologous CAR T cell therapy rese-cel at the ASGCT 2026 Annual Meeting. The data showed that the lowest dose of preconditioning-free rese-cel produced compelling drug-free responses in half of treated refractory patients with pemphigus vulgaris over six months. Additionall…

Willis Lease Finance Corporation Prices Upsized Convertible Senior Notes Offering and Borrowed Common Stock Offering to Facilitate Hedging Transactions

Willis Lease Finance Corporation Prices Upsized Convertible Senior Notes Offering and Borrowed Common Stock Offering to Facilitate Hedging Transactions

Willis Lease Finance Corporation announced the pricing of an upsized public offering of $200 million of 2.50% convertible senior notes due 2031, alongside a concurrent offering of borrowed common stock to facilitate hedging transactions. The net proceeds are intended to temporarily repay amounts outstanding under the Company's revolving credit faci…

Ducommun Incorporated to Host Investor Day on September 17, 2026

Ducommun Incorporated to Host Investor Day on September 17, 2026

Ducommun Incorporated will host an Investor Day on September 17, 2026, to update shareholders on progress under its VISION 2027 strategy and to unveil its new five-year strategic plan, VISION 2032. The company plans to highlight growth, investment, and capital allocation strategies aimed at strengthening the company and enhancing shareholder value.…

Kymeta Joins Red Cat Futures Initiative to Advance Resilient Connectivity for Autonomous Maritime Operations

Kymeta Joins Red Cat Futures Initiative to Advance Resilient Connectivity for Autonomous Maritime Operations

Red Cat Holdings announced that Kymeta has joined its Red Cat Futures Initiative, with Kymeta's satellite communication technology integrated into Blue Ops Variant 7 uncrewed surface vessels (USVs). This partnership enables reliable, resilient, and multi-orbit satellite connectivity for autonomous maritime operations, enhancing range, coordination,…

Cheetah Net Supply Chain Service Inc. Announces First Quarter 2026 Results and Provides Corporate Update

Cheetah Net Supply Chain Service Inc. Announces First Quarter 2026 Results and Provides Corporate Update

Cheetah Net Supply Chain Service Inc. reported an 80.7% revenue decline in Q1 2026 to $92,700 compared to Q1 2025, primarily due to reduced business in its acquired subsidiaries and global trade uncertainties. However, operating losses narrowed by 20.4%, driven by cost-cutting efforts. The company also secured private placement and ATM financing an…

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

Editas Medicine reported strong preclinical data demonstrating that a single dose of its lead in vivo gene editing candidate, EDIT-401, achieved significant and durable LDL-C reduction in non-human primates, supporting its potential as a one-time treatment for hyperlipidemia. The data showed a rapid, substantial, and sustained effect with a favorab…

Reliance Global Group Announces Reverse Stock Split

Reliance Global Group Announces Reverse Stock Split

Reliance Global Group, Inc. disclosed a 1-for-40 reverse stock split effective May 15, 2026, aimed at restoring compliance with Nasdaq's $1.00 minimum bid price requirement. The split will reduce the number of shares outstanding, adjusting the stock price upwards accordingly. The company's CEO emphasized commitment to the business strategy and opti…

LanzaTech Reports First Quarter 2026 Financial Results

LanzaTech Reports First Quarter 2026 Financial Results

LanzaTech Global, Inc. reported its Q1 2026 financial results, highlighting significant improvements including a 59% reduction in operating expenses, a net loss reduction to $14.7 million from $19.2 million year-over-year, and increased revenues to $12 million. The company successfully closed multiple private placements raising $30 million, which a…

Shell plc - Report on Payments to Governments for the year 2025

Shell plc - Report on Payments to Governments for the year 2025

Shell plc has released its comprehensive Report on Payments to Governments for 2025, fulfilling disclosure obligations under UK, Dutch, and U.S. regulations. The report details the payments made to governments worldwide from Shell's extractive activities, including production entitlements, taxes, royalties, bonuses, fees, and infrastructure investm…

Eight Directions Technology Limited Announces Entering into an Agreement and Plan of Merger with Quartzsea Acquisition Corporation

Eight Directions Technology Limited Announces Entering into an Agreement and Plan of Merger with Quartzsea Acquisition Corporation

Eight Directions Technology Limited, a provider of premium customized disposable products, has entered into a definitive merger agreement with Quartzsea Acquisition Corporation, a Nasdaq-listed special purpose acquisition company (SPAC). The transaction values Eight Directions at approximately $515 million in pre-money equity value and will result …

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

Propanc Biopharma, a biopharmaceutical company developing novel cancer treatments, has approved a 1-for-25 reverse stock split effective May 18, 2026, aimed at restoring compliance with Nasdaq's $1.00 minimum bid price requirement and supporting its clinical development progress. The reverse split will reduce the number of outstanding shares while …